期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺癌相关治疗与间质性肺病 被引量：9

Interstitial Lung Disease Associated with Lung Cancer Treatment
暂未订购
导出
摘要 间质性肺病是肺癌相关治疗引起的严重副反应之一,因诊断的复杂性及病情的多变性往往不能及时诊治甚至危及患者的生命,严重影响患者的预后。放、化疗及靶向治疗导致间质性肺炎的机制及相关因素尚不完全清楚。因此,如何减少、早期发现及诊治肺癌相关治疗引起的间质性肺病成为今后肺癌治疗过程中不可忽略的一个问题。 Interstitial lung disease is one of the most serious side effects caused by lung cancer treatment. Due to the complexity diagnosis and variability of the disease, it is often not diagnosied and treated in timej even endanger the patient＇s life and affect the patient＇s prognosis. The mechanism of interstitial pneumonia caused by radiotherapy, chemotherapy and targeted therapy is still not fully known. Thereforej it become a problem that how to early detection, diagnosis and treat the interstitial lung disease caused by lung cancer treatment and it should not be ignored in the future.
作者 曹志伟 金时 于雁
机构地区 哈尔滨医科大学附属肿瘤医院肿瘤内科
出处 《中国肺癌杂志》 CAS 北大核心 2013年第5期267-272,共6页 Chinese Journal of Lung Cancer
关键词 肺肿瘤 间质性肺病 放疗 化疗 靶向治疗 Lung neoplasms Interstitial lung disease Radiotherapy Chemotherapy Targeted therapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献45

  • 1Youlden DR, Cramb SM, Baade PD. The international epidemiology of lungcancer: geographical distribution and secular trends. J Thorac Oncol, 2008,3(8):819-831.
  • 2Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet, 2011,378(12): 1727-1740.
  • 3Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung diseaseand its association with lung cancer. Br J Cancer, 2004, 91(2): S3-S10.
  • 4Miyazaki K, Satoh H, Kurishima K, et al Interstitial lung disease in patientswith small cell lung cancer. Med Oncol, 2010, 27(3): 763-767.
  • 5Schwaiblmair M, Behr W, Haeckel T, et al. Drug induced interstitial lungdisease. Open Respir Med J, 2012,6(6): 63-74.
  • 6Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.Med Oncol, 2006, 23(2): 161-170.
  • 7Tamiya A, Naito T,Miura S, et al. Interstitial lung disease associated withdocetaxel in patients with advanced non-small cell lung cancer. AanticancerRes, 2012, 32(3): 1103-1106.
  • 8Okuda K, Hirose T, Oki Y, et al. Evaluation of the safety and efficacy ofcombination chemotherapy with vinorelbine and platinum agents forpatients with non-small cell lung cancer with interstitial lung disease.Anticancer Res, 2012, 32(12): 5475-5480.
  • 9Shukuya T, Ishiwata T, Hara M, et al. Carboplatin plus weekly paclitaxeltreatment in non-small cell lung cancer patients with interstitial lung disease.Anticancer Res, 2010, 30(10): 4357-4361.
  • 10Umemura S, Yamane H, Suwaki T, et al. Interstitial lung disease associatedwith gemcitabine treatment in patients with non-small-cell lung cancer andpancreatic cancer. J Cancer Res Clin Oncol, 2011,137(10): 1469-1475.

二级参考文献18

  • 1王晴,周建英.间质性肺病的治疗进展[J].国际呼吸杂志,2007,27(9):676-680. 被引量：8
  • 2Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small- cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
  • 3Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-smaU-lung cancer: a multi-centre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 2010, 11 (6): 521-529.
  • 4Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer, 2004, 45 (1): 93-104.
  • 5Cohen MH, Johnson JR, Chen YF, et al. FDA approval summary: erlotinib (tarceva) tablets. Oncologists, 2005, 10 (7): 461-466.
  • 6Kataoka K, Taniguchi H, Hasegawa Y, et al. Interstitial lung disease associated with gefitinib. Respir Med, 2006, 100(4): 698-704.
  • 7Yamamoto N, Horiike A, Fujisaka Y, et aI. Phase I dose-finding and pharmacoldnetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol, 2008, 61 (3): 489-496.
  • 8Tsubata Y, Hamada A, Sutani A, et al. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient. J Cancer Res Ther, 2012, 8(1): 154-156.
  • 9ter Heine R, van den Bosch RT, Schaefer-Prokop CM, et al. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung Cancer, 2012, 75(3): 391-397.
  • 10Makris D, Scherpereel A, Copin MC, et al. Fatal interstitial lung disease associated with oral erlotinib therapy/:or lung cancer. BMC Cancer, 2007, 7: 150.

共引文献9

同被引文献68

引证文献9

二级引证文献97

中国肺癌杂志
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部